Single-dose of integrated bilayer microneedles for enhanced hypertrophic scar therapy with rapid anti-inflammatory and sustained inhibition of myofibroblasts
Source abstract
Abstract
Hypertrophic scar (HS) tends to raised above skin level with high inflammatory microenvironment and excessive proliferation of myofibroblasts. The HS therapy remains challenging due to dense scar tissue which makes it hard to penetrate, and the side effects resulting from intralesional corticosteroid injection which is the mainstay treatment in clinic. Herein, bilayer microneedle patches combined with dexamethasone and colchicine (DC-MNs) with differential dual-release pattern is designed. Two drugs loaded in commercially available materials HA and PLGA, respectively. Specifically, after administration, outer layer rapidly releases the anti-inflammatory drug dexamethasone, which inhibits macrophage polarization to pro-inflammatory phenotype in scar tissue. Subsequently, inner layer degrades sustainedly, releasing antimicrotubular agent colchicine, which suppresses the overproliferation of myofibroblasts with extremely narrow therapeutic window, and inhibits the overexpression of collagen, as well as promotes the regular arrangement of collagen. Only applied once, DC-MNs directly delivered drugs to the scar tissue. Compared to traditional treatment regimen, DC-MNs significantly suppressed HS at lower dosage and frequency by differential dual-release design. Therefore, this study put forward the idea of integrated DC-MNs accompany the development of HS, providing a non-invasive, self-applicable, more efficient and secure strategy for treatment of HS.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Dermatologic Treatments and Research · Advancements in Transdermal Drug Delivery · Wound Healing and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. Skin scarring10.1136/bmj.326.7380.88 ↗
2. Update on management of keloid and hypertrophic scars: a systemic review10.1111/jocd.14310 ↗
3. Hypertrophic scarring: the greatest unmet challenge after burn injury10.1016/S0140-6736(16)31406-4 ↗
4. The role of macrophages in the formation of hypertrophic scars and keloids10.1093/burnst/tkaa006 ↗
5. A review of the effectiveness of antimitotic drug injections for hypertrophic scars and keloids10.1097/SAP.0b013e3181978753 ↗
6. The roles of inflammation in keloid and hypertrophic scars10.3389/fimmu.2020.603187 ↗
7. Macrophage phenotypes during tissue repair10.1189/jlb.1012512 ↗
8. Dexamethasone10.1016/S0099-5428(08)60039-8 ↗
9. The role of glucocorticoid receptor and gene expression in the anti-inflammatory action of dexamethasone10.1038/280408a0 ↗
10. 6 - anti-inflammatory effects of corticosteroids10.1016/S0260-4639(22)00182-7 ↗
11. Efficacy and safety of triamcinolone acetonide alone and in combination with 5-fluorouracil for treating hypertrophic scars and keloids: a systematic review and meta-analysis10.1111/iwj.12629 ↗
12. Intralesional bleomycin versus intralesional triamcinolone in the treatment of keloids and hypertrophic scars10.1111/dth.15730 ↗
13. Side effects of corticosteroid therapy10.1097/00004836-200110000-00006 ↗
14. Systemic absorption and side effects of locally injected glucocorticoids10.1002/pmrj.12042 ↗
15. Colchicine poisoning: the dark side of an ancient drug10.3109/15563650.2010.495348 ↗
16. Colchicine: old and new10.1016/j.amjmed.2014.12.010 ↗
17. Colchicine in clinical medicine. A guide for internists10.1016/j.ejim.2010.09.010 ↗
18. Dissolving microneedles: applications and growing therapeutic potential10.1016/j.jconrel.2022.05.045 ↗
19. Dissolving microneedles for transdermal drug delivery: advances and challenges10.1016/j.biopha.2017.07.019 ↗
20. Strategy for hypertrophic scar therapy: improved delivery of triamcinolone acetonide using mechanically robust tip-concentrated dissolving microneedle array10.1016/j.jconrel.2019.05.038 ↗
21. Bilayer dissolving microneedle array containing 5-fluorouracil and triamcinolone with biphasic release profile for hypertrophic scar therapy
22. Transdermal delivery of Chinese herbal medicine extract using dissolvable microneedles for hypertrophic scar treatment10.1016/j.apsb.2021.03.016 ↗
23. Intradermal delivery of an angiotensin II receptor blocker using a personalized microneedle patch for treatment of hypertrophic scars10.1039/D2BM01631A ↗
24. Differential dual-release bilayer microneedles loaded with aluminum adjuvants as a safe and effective vaccine platform10.1002/adfm.202201952 ↗
25. PROTAC degraders of androgen receptor-integrated dissolving microneedles for androgenetic alopecia and recrudescence treatment via single topical administration10.1002/smtd.202201293 ↗
26. Dissolving polymer microneedle patches for influenza vaccination10.1038/nm.2182 ↗
27. Human hypertrophic and keloid scar models: principles, limitations and future challenges from a tissue engineering perspective10.1111/exd.12419 ↗
28. Experimental models for cutaneous hypertrophic scar research10.1111/wrr.12760 ↗
29. Acute and chronic animal models for excessive dermal scarring: quantitative studies10.1097/00006534-199709000-00021 ↗
30. Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein10.1083/jcb.124.1.171 ↗
31. Extracellular matrix regulates expression of the TGF-beta 1 gene10.1083/jcb.120.1.253 ↗
32. Transdermal drug delivery10.1038/nbt.1504 ↗
33. Microneedles: a smart approach and increasing potential for transdermal drug delivery system10.1016/j.biopha.2018.10.078 ↗
34. Drug-eluting microneedles for self-administered treatment of keloids10.1142/S2339547814500137 ↗
35. Microneedle physical contact as a therapeutic for abnormal scars10.1186/s40001-017-0269-6 ↗
36. Microneedling for the treatment of scars: an update for clinicians10.2147/CCID.S267192 ↗
37. Transdermal delivery of Protocatechuic aldehyde using hyaluronic acid/gelatin-based microneedles for the prevention and treatment of hypertrophic scars10.1016/j.ejpb.2023.02.003 ↗
38. PLGA based drug delivery systems: promising carriers for wound healing activity10.1111/wrr.12404 ↗